Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) – Research analysts at B. Riley lifted their FY2024 earnings estimates for Mirati Therapeutics in a report released on Monday, July 24th. B. Riley analyst K. Patel now forecasts that the biotechnology company will post earnings per share of ($9.27) for the year, up from their previous estimate […]
Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its price objective cut by B. Riley from $51.00 to $45.00 in a research note released on Monday, Marketbeat.com reports. They currently have a neutral rating on the biotechnology company’s stock. B. Riley also issued estimates for Mirati Therapeutics’ FY2024 earnings at ($9.27) EPS and FY2025 earnings at […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) has earned an average recommendation of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among […]
Armistice Capital LLC lifted its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) by 83.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,488,000 shares of the biotechnology company’s stock after purchasing an additional 1,588,000 shares during the quarter. Mirati Therapeutics comprises about […]
Tang Capital Management LLC grew its holdings in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) by 200.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,000 shares of the biotechnology company’s stock after buying an additional 40,000 shares during the period. […]